S170 The analysis of the relationship between Gleason Score and Positive Core Account of the biopsy in patients with the diagnosis of prostate cancer

2013 ◽  
Vol 12 (4) ◽  
pp. e1278, S170
Author(s):  
M.B. Yuksel ◽  
A. Karakose ◽  
S.N. Gorgel ◽  
N. Pirincci ◽  
Y.Z. Atesci ◽  
...  
2009 ◽  
Vol 9 ◽  
pp. 1040-1045 ◽  
Author(s):  
Chad W. M. Ritenour ◽  
John T. Abbott ◽  
Michael Goodman ◽  
Naomi Alazraki ◽  
Fray F. Marshall ◽  
...  

Utilization of nuclear bone scans for staging newly diagnosed prostate cancer has decreased dramatically due to PSA-driven stage migration. The current criteria for performing bone scans are based on limited historical data. This study evaluates serum PSA and Gleason grade in predicting positive scans in a contemporary large series of newly diagnosed prostate cancer patients. Eight hundred consecutive cases of newly diagnosed prostate cancer over a 64-month period underwent a staging nuclear scan. All subjects had histologically confirmed cancer. The relationship between PSA, Gleason grade, and bone scan was examined by calculating series of crude, stratified, and adjusted odds ratios with corresponding 95% confidence intervals. Four percent (32/800) of all bone scans were positive. This proportion was significantly lower in patients with Gleason score ≤7 (1.9%) vs. Gleason score ≥8 (18.8%,p< 0.001). Among patients with Gleason score ≤7, the rate of positive bones scans was 70-fold higher when the PSA was >30 ng/ml compared to ≤30 ng/ml (p< 0.001). For Gleason score ≥8, the rate was significantly higher (27.9 vs. 0%) when PSA was >10 ng/ml compared to ≤10 ng/ml (p= 0.002). The combination of Gleason score and PSA enhances predictability of bone scans in newly diagnosed prostate cancer patients. The PSA threshold for ordering bone scans should be adjusted according to Gleason score. For patients with Gleason scores ≤7, we recommend a bone scan if the PSA is >30 ng/ml. However, for patients with a high Gleason score (8–10), we recommend a bone scan if the PSA is >10 ng/ml.


2014 ◽  
Vol 86 (4) ◽  
pp. 336 ◽  
Author(s):  
Pietro Pepe ◽  
Antonio Garufi ◽  
Giandomenico Priolo ◽  
Giuseppe Dibenedetto ◽  
Michele Salemi ◽  
...  

Introduction. Multiparametric pelvic magnetic resonance imaging (mpMRI) accuracy in prostate cancer (PCa) diagnosis was evaluated. Materials and Methods. From June 2011 to December 2013, 168 patients (median 65 years) with negative digital rectal examination underwent repeat transperineal saturation biopsy (SPBx; median 28 cores) for persistently high or increasing PSA values, PSA &gt;10 ng/ml or PSA values between 4.1-10 o r 2.6-4 ng/ml with free/total PSA &lt; 25% and &lt; 20%, respectively. All patients underwent mpMRI using a 3.0 Tesla scanner equipped with surface 16 channels phased-array coil and lesions suspicious for PCa were submitted to additional targeted biopsies. Results. A T1c PCa was found in 66 (39%) cases; SPBx and mpMRI-suspicious targeted biopsy diagnosed 60 (91%) and 52 (78.8%) cancers missing 6 (all of the anterior zone) and 14 cancers (12 and 2 of the lateral margins and anterior zone), respectively; in detail, mpMRI missed 12 (18.1%) PCa charaterized by microfocal (1 positive core with greatest percentage of cancer and Gleason score equal to 5% and 6, respectively) disease at risk for insignificant cancer. The diameter of the suspicious mpMRI lesion was directly correlated to the diagnosis of PCa with poor Gleason score (p &lt; 0.05); detection rate of cancer for each suspicious mpMRI core was 35.3%. Diagnostic accuracy, sensitivity, specificity, positive and negative predictive value of mpMRI in diagnosing PCa was 75.7%, 82.5%, 71.8%, 78.9%, 87.9%, respectively. Conclusion. Multiparametric pMRI improved SPBx accuracy in diagnosing significant anterior PCa; the diameter of mpMRI suspicious lesion resulted significantly predictive of aggressive cancers.


2021 ◽  
Vol 3 (4) ◽  
pp. 327-332
Author(s):  
Şadiye ALTUNTUZCU ◽  
Bekir TAŞDEMİR ◽  
İhsan KAPLAN ◽  
Ali UYAR ◽  
Fatih GÜZEL ◽  
...  

2021 ◽  
Author(s):  
Jie Cui ◽  
Wei zhang ◽  
Zhenlong Wang ◽  
Yanxiang Chang ◽  
Hongyi Zhang

Abstract Background Non-alcoholic fatty liver disease (NAFLD) has been reported to be helpful to identify high-risk individuals of developing prostate cancer. In the retrospective cohort study, our aim is to investigate the relationship between NAFLD and biochemical recurrence in metastatic prostate cancer patients. Methods We retrospectively investigated 602 patients with metastatic prostate cancer receiving androgen deprivation therapy. Liver fat was estimated with liver-to-spleen ratio by CT scans. The relationship between NAFLD and biochemical recurrence was investigated with Cox models. The model for biochemical recurrence was adjusted for multiple variables. Results NAFLD was significantly associated with biochemical recurrence in patients with Gleason score ≥ 4 + 3 when adjusting for each of body mass index (hazards ratio [HR] = 1.38; 95% confidence interval [CI] = 1.08–1.77; p = 0.01), visceral adipose tissue (HR = 1.36; 95% CI = 1.07–1.74; p = 0.01), hypertension (HR = 1.41; 95% CI = 1.10–1.80; p = 0.01) and diabetes mellitus (HR = 1.42; 95% CI = 1.11–1.82; p = 0.01), using age and prostate-specific antigen level as potential confounder. The 2-year biochemical recurrence rate in Gleason score ≥ 4 + 3 patients with and without NAFLD was 84.0% (100/119) and 72.2% (130/180), respectively (p = 0.018). The median biochemical recurrence free survival of Gleason score ≥ 4 + 3 patients with and without NAFLD were 17 and 21 months, respectively (p = 0.005). Conclusions NAFLD is an independent risk factor for biochemical recurrence in patients with high-grade metastatic prostate cancer. If validated in prospective studies, future research should test whether treatment of NAFLD can lead to better prognosis.


The Prostate ◽  
2010 ◽  
Vol 70 (15) ◽  
pp. 1683-1691 ◽  
Author(s):  
Erica E. Hack ◽  
D. Robert Siemens ◽  
Patti A. Groome

2022 ◽  
Vol 3 (1) ◽  
pp. 01-05
Author(s):  
Omar Alqawi ◽  
Eman Elshahmi ◽  
Fatma Emaetig ◽  
Fauzia Elgaraboli ◽  
Abubaker Abushnaf

Background: Prostate cancer is the second most frequent cancer and the fifth leading cause of cancer death in men with higher prevalence in the developed countries. The use of biomarkers for prostate cancer can improve the diagnosis of prostate cancer and clinical management of the patients. Prostate-specific antigen (PSA) is widely used to screen for prostate cancer and there is evidence that PSA testing reduces prostate cancer mortality. Objective: In this report we have studied the relationship between the Gleason score, age and PSA levels of prostate adenocarcinoma tissues from Libyan patients to evaluate the levels of PSA in prostate cancer patients. Materials and methods: The data was collected from medical files of 40 patients who underwent curative surgical prostatectomy or prostate true cut biopsy at National Cancer Institute (NCI)-Misurata, Libya during 2016 to 2018. The clinical and histopathological information included age, PSA levels, and Gleason score grade. Results: Our data showed that PSA level was statistically significant correlation with Gleason score grade (p- value = 0.007, <0.05). The increased serum PSA level was associated with the progression of prostate cancer. However, we found no statistically significant correlation between PSA and the age of patients (p- value = 0.435). Conclusion: Our data confirmed the association of high levels of PSA and the progress of prostate cancer.


2013 ◽  
Vol 2 (5) ◽  
pp. 518 ◽  
Author(s):  
Ken J. Newell ◽  
John F. Amrhein ◽  
Rashmikant J. Desai ◽  
Paul F. Middlebrook ◽  
Todd M. Webster ◽  
...  

Objective: Transrectal ultrasound–guided core biopsies of the prostate gland and prostatectomies have become common procedures at many community hospitals in Canada, especially in the era of serum prostate-specific antigen (PSA) screening for prostate cancer. The Gleason grading of prostate cancer in biopsies and prostatectomies is a major determinant used for treatment planning. There is evidence in the literature that suggests important discordance between community hospital pathologists and urological pathologists with respect to the Gleason grading of prostate cancer. Our objective was to determine the diagnostic rates and Gleason scoring patterns for prostate gland biopsies and prostatectomies at our institution compared with the literature.Methods: We conducted a retrospective review of all prostate gland biopsies and prostatectomies performed at the Grey Bruce Health Services from January 2005 to September 2005. We collected data from 194 biopsies and 44 prostatectomies. We obtained prebiopsy serum PSA levels and digital rectal exam results for all patients from urologists’ office records.Results: The average age for men having biopsies was 65.8 (standard deviation [SD] 8.6) years, and the average prebiopsy serum PSA level was 8.7 (median 7.1, SD 6.2) μg/L. The rates of diagnosis from prostate gland biopsies of benign (17.6%), high-grade prostatic intraepithelial neoplasia (11.0%), atypical small acinar proliferation suspicious for invasive malignancy (13.2%) and invasive prostatic adenocarcinoma (58.2%) at our institution were significantly different than those reported in the literature (p < 0.001). We observed a significant variation in the rates of these diagnoses among the community hospital pathologists in our study (p = 0.004). There was a strong correlation between the increasing number of positive core biopsy sites and increasing Gleason scores in biopsies (p < 0.001). There was also a strong correlation between increasing prebiopsy serum PSA levels and increasing Gleason scores in biopsies (p < 0.001). A substantial proportion (21.9%) of the biopsies given the Gleason score of 6 had a Gleason score of 7 in the prostatectomy specimen.Conclusion: Our results showed a significant difference in prostate gland biopsy categorical diagnoses compared with the literature. There were also significant differences in categorical diagnoses of prostate gland biopsies among the community hospital pathologists in our study. The data identify a strong positive correlation between the increasing number of positive core biopsy sites and increasing Gleason scores in biopsies, as well as a strong positive correlation between increasing prebiopsy serum PSA levels and increasing Gleason scores in biopsies that revealed cancer. We would encourage other community hospital pathologists, in collaboration with their urologists, to review periodically their prostate gland pathology practices in an attempt to improve the uniformity of diagnoses.


The Prostate ◽  
2015 ◽  
Vol 75 (10) ◽  
pp. 1034-1042 ◽  
Author(s):  
Kouji Izumi ◽  
Hiroko Ikeda ◽  
Aerken Maolake ◽  
Kazuaki Machioka ◽  
Takahiro Nohara ◽  
...  

2021 ◽  
Vol 6 (2) ◽  
pp. 147-153
Author(s):  
Martin Igbokwe ◽  
Ayo Salako ◽  
Tajudeen Badmus ◽  
Eusebius Obiajunwa ◽  
Olalekan Olasehinde ◽  
...  

Introduction: Prostate cancer (PCa) is the commonest maliganacy among men of African descent. The possible role of trace elements like Zinc in its aetiogenesis and disease severity remains controversial. This paper aims to identify the relationship between tissue zinc concentration and the occurrence of prostate cancer. And to identify the relationship between the tissue zinc concentration and the disease severity (using the prostate specific antigen (PSA) and Gleason scores (GS)).Methodology: A cross-sectional study of 41 consecutive consenting men with histologically confirmed PCa and 41 age-matched controls. Toe-nail clippings were obtained from both groups and assayed for zinc using the Particle induced X-ray emission (PIXE) technique. Zinc concentrations were compared between cases and controls. A correlation analysis was performed to determine relationship between Zinc concentration and disease severity (PSA and GS). Results: Forty one men each were recruited in the Prostate cancer and control groups for this study. PCa group had a mean age of 72.83 ± 7.06 years while the control group was 70.73 ±6.40 years. There was statistically significant higher toe-nail Zn concentration among Prostate cancer patients than controls (P= 0.028, t=2.28, df=40). The mean PSA values among the Prostate cancer group was 46.10 ± 40.62ng/ml and mode GS was 8.There was neither a correlation between toe-nail Zn concentration and serum PSA levels (p=0.386) nor with the GS. Conclusion: This study found a statistically significant higher toe-nail Zn concentration among men with PCa compared with age-matched controls. There was however no correlation between toe-nail Zn concentration and the serum prostate specific antigen or Gleason score.


Sign in / Sign up

Export Citation Format

Share Document